AstraZeneca PLC (AZN) operating KPIs

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30

$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca breztri Aerosphere (budesonide/glycopyrronium/formoterol) — Worldwide product sales ($M) ($M)

Form 6-K Quarterly & Form 20-F Product Sales by Medicine & Region Tables

Quarterly Annual

Latest, Q2 2026

346

Period ended Jun 30, 2026

Change on a year earlier

+22.3%

283 in Q2 2025

History

28 quarters

Since Q3 2019

Sources

Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

Period	Ended	Breztri Aerosphere (budesonide/glycopyrronium/formoterol) — Worldwide product sales ($M) ($M)	Year on year	Source
Q2 2026	Jun 30, 2026	346	+22.3%	Form 6-K FY2026Q2 Earnings Release ↗
Q1 2026	Mar 31, 2026	353	+17.7%	Form 6-K FY2026Q1 Earnings Release ↗
Q4 2025	Dec 31, 2025	294	+14.4%	Form 6-K FY2025Q4 Earnings Release ↗
Q3 2025	Sep 30, 2025	323	+21.4%	Form 6-K FY2025Q3 Earnings Release ↗
Q2 2025	Jun 30, 2025	283	+20.4%	Form 6-K FY2025Q2 Earnings Release ↗
Q1 2025	Mar 31, 2025	300	+37.0%	Form 6-K FY2025Q1 Earnings Release ↗
Q4 2024	Dec 31, 2024	257	+29.1%	Form 6-K FY2024Q4 Earnings Release ↗
Q3 2024	Sep 30, 2024	266	+55.6%	Form 6-K FY2024Q3 Earnings Release ↗
Q2 2024	Jun 30, 2024	235	+44.2%	Form 6-K FY2024Q2 Earnings Release ↗
Q1 2024	Mar 31, 2024	219	+52.1%	Form 6-K FY2024Q1 Earnings Release ↗
Q4 2023	Dec 31, 2023	199	+71.6%	Form 6-K FY2023Q4 Earnings Release ↗
Q3 2023	Sep 30, 2023	171	+66.0%	Form 6-K FY2023Q3 Earnings Release ↗
Q2 2023	Jun 30, 2023	163	+75.3%	Form 6-K FY2023Q2 Earnings Release ↗
Q1 2023	Mar 31, 2023	144	+65.5%	Form 6-K FY2023Q1 Earnings Release ↗
Q4 2022	Dec 31, 2022	116	+58.9%	Form 6-K FY2022Q4 Earnings Release ↗
Q3 2022	Sep 30, 2022	103	+119.1%	Form 6-K FY2022Q3 Earnings Release ↗
Q2 2022	Jun 30, 2022	93	+66.1%	Form 6-K FY2022Q2 Earnings Release ↗
Q1 2022	Mar 31, 2022	87	+222.2%	Form 6-K FY2022Q1 Earnings Release ↗
Q4 2021	Dec 31, 2021	73	+1,116.7%	Form 6-K FY2021Q4 Earnings Release ↗
Q3 2021	Sep 30, 2021	47	+370.0%	Form 6-K FY2021Q3 Earnings Release ↗
Q2 2021	Jun 30, 2021	56	+700.0%	Form 6-K FY2021Q2 Earnings Release ↗
Q1 2021	Mar 31, 2021	27	+575.0%	Form 6-K FY2021Q1 Earnings Release ↗
Q4 2020	Dec 31, 2020	6	+500.0%	Form 6-K FY2020Q4 Earnings Release ↗
Q3 2020	Sep 30, 2020	10	+900.0%	Form 6-K (filed 2021-07-30) ↗
Q2 2020	Jun 30, 2020	7	–	Form 6-K/A (filed 2020-07-31) ↗
Q1 2020	Mar 31, 2020	4	–	Form 6-K/A (filed 2020-07-31) ↗
Q4 2019	Dec 31, 2019	1	–	Form 6-K/A (filed 2020-07-31) ↗
Q3 2019	Sep 30, 2019	1	–	Form 6-K/A (filed 2020-07-31) ↗

Breakdown

What makes up breztri aerosphere (budesonide/glycopyrronium/formoterol) — worldwide product sales ($m)

Cite this data

StockData. (2026). AstraZeneca Breztri Aerosphere (budesonide/glycopyrronium/formoterol) — Worldwide product sales ($M) ($M), quarterly Q3 2019–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med_breztri_world

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.